Results In RA synovial tissue expression of FoxO1 negatively correlated with clinical parameters of disease activity: serum C-reactive protein (R = −0.771, P = 0.0008), erythrocyte sedimentation rate (R = −0.759, P = 0.0003), and DAS28 (R = −0.575, P = 0.01), as well as synovial IL-6 mRNA levels (R = −0.628, P = 0.004). In vitro, RA FLS stimulation with IL-1β or TNFα caused rapid down-regulation of FoxO1 mRNA levels, followed by reduction of FoxO1 protein expression and DNA binding. This effect was independent of PKB signalling, and was associated with acceleration of FoxO1 mRNA degradation in the presence of IL-1β. Inhibition of c-Jun N-terminal kinase (JNK), but not other MAPKs, prevented down-regulation of FoxO1 expression and binding by IL-1β, and blocked IL-1β-induced reduction of FoxO1 mRNA stability. Overexpression of constitutively active FoxO1 in RA FLS induced apoptosis associated with altered expression of genes regulating cell cycle and apoptosis: BIM and p27(kip). were induced while expression of Bcl-XL was suppressed in cells expressing active FoxO1.

Conclusions Collectively, our findings suggest that suppressed synovial FoxO1 expression is strongly associated with RA pathology and demonstrate that reduction of FoxO1 expression might contribute to perpetuation of inflammation in RA by promoting FLS survival and proliferation. Our data also identify JNK-mediated modulation of FoxO1 mRNA stability as an important mechanism underlying regulation of FoxO1 by inflammatory cytokines.

A10.18 LACK OF ASSOCIATION OF SERUM INTERLEUKIN-17 AND INTERLEUKIN-23 LEVELS WITH DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN LATVIA

doi:10.1136/annrheumdis-2013-203224.18

1Zepa Julija, 1Bulina Inita, 2Nikita-Zaik Laine, 2Klovins Janis, 3Jurka Anita, 4Tretjakovs Peteris, 2Lejnieks Ainars, 3Andersone Daina. 4Pauls Stradins Clinical University Hospital; 2Riga Stradins University; 2Biomedical Research and Study Centre of Latvia; 3Riga East Clinical University Hospital; 4University of Latvia, Latvia

Background Ankylosing spondylitis (AS) is a clinically well-known chronic inflammatory disease of the axial skeleton and peripheral joints. The pathogenesis of this disease still remains a challenge. Determination of cytokine profile and its role involved in AS pathogenesis give an opportunity to extend the targeted therapeutic approach. Interleukin-17 (IL-17) and interleukin-23 (IL-23) are cytokines of interest in the investigation of the pathogenesis of spondyloarthritides although their importance in AS is not clearly defined.

Objectives to investigate levels of IL-17 and IL-23 in a group of AS and in a demographically matched group of healthy subjects and its association with the disease activity measured by relevant clinical and biochemical parameters.

Materials and Methods 39 AS patients classified by the modified New York and ASAS criteria were assessed clinically and 6 ml of serum were collected from each patient. 39 healthy subjects as control group were included in this study. The serum IL-17 and IL-23 levels were tested using xMAP multiplex immunobead assay technology. At the same time the disease activity was measured by using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) using C-reactive protein (CRP), erythrocyte sedimentation rate (ESR).

Results The mean serum IL-17 and IL-23 level in AS group was respectively 18.9 (SD 39.6) and 194.6 (SD 261.4) pg/ml. In the healthy control group the mean serum IL-17 level was 15.4 (SD 39.6) and IL-23 level – 200.3 (SD 256.3) pg/ml. The serum levels of IL-17 and IL-23 were not statistically significantly different from the healthy subjects and the levels did not correlate with the disease activity measured by BASDAI and ASDAS (using the CRP and ESR).

Conclusions These results suggest that IL-17 and IL-23 are not major components of the pathogenesis of inflammation in AS patients. Our data differ from Chee W S et al, in 2012 published data of the serum IL-17 and IL-23 level association with the disease activity in Chinese patients with AS. This difference is probably due to the various genetic aspects characterising AS as geographically matched disease.